首页 > 最新文献

International journal of pharmacokinetics最新文献

英文 中文
Intersex and interspecies pharmacokinetics of metoprolol after oral and intravenous dose administration in rats and mice 美托洛尔在大鼠和小鼠体内口服和静脉给药后的雌雄和种间药代动力学
Pub Date : 2023-03-03 DOI: 10.4155/ipk-2022-0002
Yeshwant Singh, Ravi Akkireddy, Deepti Sahu, Giridhar Bilagi, Theertha Thykandy, Prajakta Hingole, Deveshkumar Rana, Roopa Naraganti, Sudhir Kumar Tiwari, P. Srivastava
Aim: Intersex and interspecies metoprolol pharmacokinetics following intravenous and oral dose administration in rodents. Materials & methods: Oral and intravenous dose studies were conducted in rats and mice. Significant intersex differences were observed in peak plasma levels of metoprolol after oral dose in both the species. The plasma concentration (Cmax) was approximately sevenfold higher (270.356 ng/ml) in female compared with male rats (40.981 ng/ml) following oral dose administration. The Cmax observed for male (878.822 ± 75.5 ng/ml) was approximately twofold higher than in female mouse (404.016 ± 113.5 ng/ml) after oral dose administration. Conclusion: Sex and species related physioanatomical characteristics alters metoprolol pharmacokinetics. Such differences should be addressed in studies related to metoprolol interactions with concurrently administered drug candidates.
目的:研究美托洛尔在啮齿类动物体内静脉和口服给药后的两性和种间药代动力学。材料与方法:对大鼠和小鼠进行口服和静脉给药研究。口服美托洛尔后,两种动物血浆中美托洛尔的峰值水平存在显著的两性差异。口服给药后,雌性大鼠的血药浓度(Cmax)为270.356 ng/ml,约为雄性大鼠(40.981 ng/ml)的7倍。口服给药后,雄性小鼠Cmax(878.822±75.5 ng/ml)比雌性小鼠(404.016±113.5 ng/ml)高约2倍。结论:性别和物种相关的生理解剖特征改变了美托洛尔的药代动力学。这些差异应该在美托洛尔与同时给药的候选药物相互作用的研究中得到解决。
{"title":"Intersex and interspecies pharmacokinetics of metoprolol after oral and intravenous dose administration in rats and mice","authors":"Yeshwant Singh, Ravi Akkireddy, Deepti Sahu, Giridhar Bilagi, Theertha Thykandy, Prajakta Hingole, Deveshkumar Rana, Roopa Naraganti, Sudhir Kumar Tiwari, P. Srivastava","doi":"10.4155/ipk-2022-0002","DOIUrl":"https://doi.org/10.4155/ipk-2022-0002","url":null,"abstract":"Aim: Intersex and interspecies metoprolol pharmacokinetics following intravenous and oral dose administration in rodents. Materials & methods: Oral and intravenous dose studies were conducted in rats and mice. Significant intersex differences were observed in peak plasma levels of metoprolol after oral dose in both the species. The plasma concentration (Cmax) was approximately sevenfold higher (270.356 ng/ml) in female compared with male rats (40.981 ng/ml) following oral dose administration. The Cmax observed for male (878.822 ± 75.5 ng/ml) was approximately twofold higher than in female mouse (404.016 ± 113.5 ng/ml) after oral dose administration. Conclusion: Sex and species related physioanatomical characteristics alters metoprolol pharmacokinetics. Such differences should be addressed in studies related to metoprolol interactions with concurrently administered drug candidates.","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84264926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between simulated ketamine exposures and oxygen saturations in children. 模拟氯胺酮暴露与儿童血氧饱和度之间的关系。
Pub Date : 2023-02-01 DOI: 10.4155/ipk-2022-0003
Sarah Jane Commander, Daniel Gonzalez, Karan R Kumar, Tracy Spears, Michael Cohen-Wolkowiez, Kanecia O Zimmerman, Jan Hau Lee, Christoph P Hornik

Aim: We performed a real-world data analysis to evaluate the relationship between simulated ketamine exposures and oxygen desaturation in children.

Materials & methods: A previously developed population pharmacokinetic model was used to simulate exposures and evaluate target attainment, as well as the association with oxygen desaturation in children ≤17 years treated with intravenous ketamine.

Results: In 2022 children, there was no significant association between simulated plasma ketamine concentrations and oxygen saturation; however, a higher cumulative area under the curve was associated with increased odds of progression to significant desaturation (<85%), though magnitude of effect was small.

Conclusion: By leveraging a population pharmacokinetic model and real-world data, we confirmed there is no relationship between simulated ketamine plasma concentration and oxygen desaturation.

目的:我们进行了真实世界的数据分析,以评估模拟氯胺酮暴露与儿童氧饱和度之间的关系。材料与方法:使用先前开发的人群药代动力学模型来模拟暴露并评估目标实现情况,以及≤17岁静脉注射氯胺酮治疗的儿童与氧去饱和的关系。结果:2022例患儿模拟血浆氯胺酮浓度与血氧饱和度无显著相关性;然而,较高的曲线下累积面积与进展到显著去饱和的几率增加相关(结论:通过利用人群药代动力学模型和真实数据,我们证实了模拟氯胺酮血浆浓度与氧去饱和之间没有关系。
{"title":"Association between simulated ketamine exposures and oxygen saturations in children.","authors":"Sarah Jane Commander,&nbsp;Daniel Gonzalez,&nbsp;Karan R Kumar,&nbsp;Tracy Spears,&nbsp;Michael Cohen-Wolkowiez,&nbsp;Kanecia O Zimmerman,&nbsp;Jan Hau Lee,&nbsp;Christoph P Hornik","doi":"10.4155/ipk-2022-0003","DOIUrl":"https://doi.org/10.4155/ipk-2022-0003","url":null,"abstract":"<p><strong>Aim: </strong>We performed a real-world data analysis to evaluate the relationship between simulated ketamine exposures and oxygen desaturation in children.</p><p><strong>Materials & methods: </strong>A previously developed population pharmacokinetic model was used to simulate exposures and evaluate target attainment, as well as the association with oxygen desaturation in children ≤17 years treated with intravenous ketamine.</p><p><strong>Results: </strong>In 2022 children, there was no significant association between simulated plasma ketamine concentrations and oxygen saturation; however, a higher cumulative area under the curve was associated with increased odds of progression to significant desaturation (<85%), though magnitude of effect was small.</p><p><strong>Conclusion: </strong>By leveraging a population pharmacokinetic model and real-world data, we confirmed there is no relationship between simulated ketamine plasma concentration and oxygen desaturation.</p>","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"6 1","pages":"IPK03"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9454753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bayesian therapeutic drug monitoring software: past, present and future 贝叶斯治疗药物监测软件:过去,现在和未来
Pub Date : 2018-12-01 DOI: 10.4155/IPK-2018-0005
P. Drennan, M. Doogue, S. V. Hal, P. Chin
{"title":"Bayesian therapeutic drug monitoring software: past, present and future","authors":"P. Drennan, M. Doogue, S. V. Hal, P. Chin","doi":"10.4155/IPK-2018-0005","DOIUrl":"https://doi.org/10.4155/IPK-2018-0005","url":null,"abstract":"","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/IPK-2018-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72533751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Personalized medicine in digital innovation 数字化创新中的个性化医疗
Pub Date : 2018-11-30 DOI: 10.4155/IPK-2018-0006
Kairui Feng, R. Leary
{"title":"Personalized medicine in digital innovation","authors":"Kairui Feng, R. Leary","doi":"10.4155/IPK-2018-0006","DOIUrl":"https://doi.org/10.4155/IPK-2018-0006","url":null,"abstract":"","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88851004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pharmacokinetic–pharmacodynamic modeling and it is relevance in the drug discovery 药代动力学-药效学建模及其与药物发现的相关性
Pub Date : 2018-09-01 DOI: 10.4155/IPK-2018-0004
S. Dubey, K. S. Pradyuth, Sreehari Krishna Kulkarni, Gautam Singhvi
{"title":"Pharmacokinetic–pharmacodynamic modeling and it is relevance in the drug discovery","authors":"S. Dubey, K. S. Pradyuth, Sreehari Krishna Kulkarni, Gautam Singhvi","doi":"10.4155/IPK-2018-0004","DOIUrl":"https://doi.org/10.4155/IPK-2018-0004","url":null,"abstract":"","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87028645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
On the reproducibility crisis in nanomedicine: an interview with Sourav Bhattacharjee 关于纳米医学的可再现性危机:采访Sourav Bhattacharjee
Pub Date : 2018-09-01 DOI: 10.4155/IPK-2018-0007
S. Bhattacharjee
Biography Sourav Bhattacharjee is a physician (MBBS) and graduated from Medical College and Hospital Kolkata (India). After postgraduate residential training in orthopedic surgery, he finished MSc in Biomolecular Sciences/Cell Biology from the Vrije Universiteit Amsterdam (2006–2008). His MSc thesis work was done in the Napier University (Edinburgh, UK). He began his PhD in the Wageningen University (The Netherlands) in 2008, which he successfully defended in 2012. Following that he worked for almost a year as postdoc in the University of Twente (The Netherlands). From March 2014, he joined UCD (Ireland) as postdoc trying to develop nanoparticulate platforms for oral insulin delivery as part of EU FP7 funded TRANS-INT consortium. From February 2016, he was appointed as Assistant Professor in the UCD where he is engaged now in developing a broad range of advanced nanobiotechnology-based and microscopic tools for effective diagnostic and therapeutic purposes in various diseases.
苏拉夫·巴塔查尔吉是一名医生(MBBS),毕业于加尔各答医学院和医院(印度)。2006-2008年,他在阿姆斯特丹自由大学(Vrije Universiteit Amsterdam)获得生物分子科学/细胞生物学硕士学位。他的硕士论文是在纳皮尔大学(爱丁堡,英国)完成的。他于2008年在荷兰瓦赫宁根大学(Wageningen University)攻读博士学位,并于2012年成功卫冕。之后,他在特温特大学(荷兰)做了将近一年的博士后。从2014年3月起,他加入UCD(爱尔兰)作为博士后,试图开发口服胰岛素的纳米颗粒平台,作为欧盟FP7资助的TRANS-INT联盟的一部分。从2016年2月起,他被任命为UCD的助理教授,在那里他现在从事开发广泛的先进的基于纳米生物技术和微观工具,用于各种疾病的有效诊断和治疗目的。
{"title":"On the reproducibility crisis in nanomedicine: an interview with Sourav Bhattacharjee","authors":"S. Bhattacharjee","doi":"10.4155/IPK-2018-0007","DOIUrl":"https://doi.org/10.4155/IPK-2018-0007","url":null,"abstract":"Biography Sourav Bhattacharjee is a physician (MBBS) and graduated from Medical College and Hospital Kolkata (India). After postgraduate residential training in orthopedic surgery, he finished MSc in Biomolecular Sciences/Cell Biology from the Vrije Universiteit Amsterdam (2006–2008). His MSc thesis work was done in the Napier University (Edinburgh, UK). He began his PhD in the Wageningen University (The Netherlands) in 2008, which he successfully defended in 2012. Following that he worked for almost a year as postdoc in the University of Twente (The Netherlands). From March 2014, he joined UCD (Ireland) as postdoc trying to develop nanoparticulate platforms for oral insulin delivery as part of EU FP7 funded TRANS-INT consortium. From February 2016, he was appointed as Assistant Professor in the UCD where he is engaged now in developing a broad range of advanced nanobiotechnology-based and microscopic tools for effective diagnostic and therapeutic purposes in various diseases.","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78074886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients 质子泵抑制剂在健康受试者中口服靶向治疗癌症患者的药代动力学相互作用数据的外推
Pub Date : 2018-09-01 DOI: 10.4155/IPK-2018-0003
N. Srinivas
{"title":"Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients","authors":"N. Srinivas","doi":"10.4155/IPK-2018-0003","DOIUrl":"https://doi.org/10.4155/IPK-2018-0003","url":null,"abstract":"","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88051130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes. 临床药代动力学-药效学研究在揭示早期和晚期结核预后决定因素中的重要性。
Pub Date : 2017-08-01 Epub Date: 2017-07-12 DOI: 10.4155/ipk-2017-0004
Andrew D McCallum, Derek J Sloan

Tuberculosis remains a major infectious cause of morbidity and mortality worldwide. Current antibiotic regimens, constructed prior to the development of modern pharmacokinetic-pharmacodynamic (PK-PD) tools, are based on incomplete understanding of exposure-response relationships in drug susceptible and multidrug resistant tuberculosis. Preclinical and population PK data suggest that clinical PK-PD studies may enable therapeutic drug monitoring for some agents and revised dosing for others. Future clinical PK-PD challenges include: incorporation of PK methods to assay free concentrations for all active metabolites; selection of appropriate early outcome measures which reflect therapeutic response; elucidation of genetic contributors to interindividual PK variability; conduct of targeted studies on special populations (including children); and measurement of PK-PD parameters at the site of disease.

结核病仍然是全世界发病率和死亡率的主要传染病。目前的抗生素方案是在现代药代动力学-药效学(PK-PD)工具发展之前构建的,是基于对药物敏感和多重耐药结核病的暴露-反应关系的不完全理解。临床前和人群PK数据表明,临床PK- pd研究可以对某些药物进行治疗性药物监测,并修改其他药物的剂量。未来的临床PK- pd挑战包括:结合PK方法来测定所有活性代谢物的游离浓度;选择反映治疗反应的适当早期结果指标;阐明个体间PK变异的遗传因素;对特殊人群(包括儿童)进行有针对性的研究;以及疾病部位PK-PD参数的测量。
{"title":"The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.","authors":"Andrew D McCallum,&nbsp;Derek J Sloan","doi":"10.4155/ipk-2017-0004","DOIUrl":"https://doi.org/10.4155/ipk-2017-0004","url":null,"abstract":"<p><p>Tuberculosis remains a major infectious cause of morbidity and mortality worldwide. Current antibiotic regimens, constructed prior to the development of modern pharmacokinetic-pharmacodynamic (PK-PD) tools, are based on incomplete understanding of exposure-response relationships in drug susceptible and multidrug resistant tuberculosis. Preclinical and population PK data suggest that clinical PK-PD studies may enable therapeutic drug monitoring for some agents and revised dosing for others. Future clinical PK-PD challenges include: incorporation of PK methods to assay free concentrations for all active metabolites; selection of appropriate early outcome measures which reflect therapeutic response; elucidation of genetic contributors to interindividual PK variability; conduct of targeted studies on special populations (including children); and measurement of PK-PD parameters at the site of disease.</p>","PeriodicalId":73468,"journal":{"name":"International journal of pharmacokinetics","volume":"2 3","pages":"195-212"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ipk-2017-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36544898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
期刊
International journal of pharmacokinetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1